{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:37:49Z","timestamp":1768250269753,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T00:00:00Z","timestamp":1349136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1743-422x-9-226","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T16:14:33Z","timestamp":1349194473000},"source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of HCV by the serpin antithrombin III"],"prefix":"10.1186","volume":"9","author":[{"given":"Mohammed","family":"Asmal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman L","family":"Letvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Geiben-Lynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,2]]},"reference":[{"key":"1929_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2012.02.012","volume":"142","author":"S Naggie","year":"2012","unstructured":"Naggie S, Sulkowski MS: Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012, 142: 1324-1334. 10.1053\/j.gastro.2012.02.012. e1323","journal-title":"Gastroenterology"},{"key":"1929_CR2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2005.11.007","volume":"44","author":"JK Rockstroh","year":"2006","unstructured":"Rockstroh JK: Influence of viral hepatitis on HIV infection. J Hepatol. 2006, 44: S25-S27.","journal-title":"J Hepatol"},{"key":"1929_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999, 30: 1054-1058.","journal-title":"The Multivirc Group. Hepatology"},{"key":"1929_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1086\/380130","volume":"38","author":"L Martin-Carbonero","year":"2004","unstructured":"Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, et al: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004, 38: 128-133. 10.1086\/380130.","journal-title":"Clin Infect Dis"},{"key":"1929_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1086\/367643","volume":"36","author":"C Martinez-Sierra","year":"2003","unstructured":"Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, Giron-Gonzalez JA: Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003, 36: 491-498. 10.1086\/367643.","journal-title":"Clin Infect Dis"},{"key":"1929_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/318501","volume":"32","author":"I Bica","year":"2001","unstructured":"Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001, 32: 492-497. 10.1086\/318501.","journal-title":"Clin Infect Dis"},{"key":"1929_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1097\/00002030-200308150-00009","volume":"17","author":"E Rosenthal","year":"2003","unstructured":"Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003, 17: 1803-1809. 10.1097\/00002030-200308150-00009.","journal-title":"AIDS"},{"key":"1929_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00126334-200310010-00006","volume":"34","author":"KA Gebo","year":"2003","unstructured":"Gebo KA, Diener-West M, Moore RD: Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr. 2003, 34: 165-173. 10.1097\/00126334-200310010-00006.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1929_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.qai.0000174930.64145.a9","volume":"40","author":"YC Gilleece","year":"2005","unstructured":"Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR: Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005, 40: 41-46. 10.1097\/01.qai.0000174930.64145.a9.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1929_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006, 13: 34-41. 10.1111\/j.1365-2893.2005.00651.x.","journal-title":"J Viral Hepat"},{"key":"1929_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/01.aids.0000226956.02719.fd","volume":"20","author":"S Dominguez","year":"2006","unstructured":"Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, Pialoux G, Benhamou Y, Thibault V, Katlama C: Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006, 20: 1157-1161. 10.1097\/01.aids.0000226956.02719.fd.","journal-title":"AIDS"},{"key":"1929_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","volume":"130","author":"SM Kamal","year":"2006","unstructured":"Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, He Q, Khalifa KE, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH: Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006, 130: 632-638. 10.1053\/j.gastro.2006.01.034.","journal-title":"Gastroenterology"},{"key":"1929_CR13","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMoa011232","volume":"345","author":"E Jaeckel","year":"2001","unstructured":"Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001, 345: 1452-1457. 10.1056\/NEJMoa011232.","journal-title":"N Engl J Med"},{"key":"1929_CR14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","volume":"27","author":"M Nunez","year":"2001","unstructured":"Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001, 27: 426-431.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1929_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0025-7753(01)72194-X","volume":"117","author":"R Lana","year":"2001","unstructured":"Lana R, Nunez M, Mendoza JL, Soriano V: Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. Med Clin (Barc). 2001, 117: 607-610.","journal-title":"Med Clin (Barc)"},{"key":"1929_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000, 283: 74-80. 10.1001\/jama.283.1.74.","journal-title":"JAMA"},{"key":"1929_CR17","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","volume":"18","author":"S Mauss","year":"2004","unstructured":"Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D: Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004, 18: F21-F25.","journal-title":"AIDS"},{"key":"1929_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","volume":"40","author":"F Bani-Sadr","year":"2005","unstructured":"Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, et al: Risk factors for symptomatic mitochondrial toxicity in HIV\/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005, 40: 47-52. 10.1097\/01.qai.0000174649.51084.46.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1929_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa032653","volume":"351","author":"RT Chung","year":"2004","unstructured":"Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, et al: Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004, 351: 451-459. 10.1056\/NEJMoa032653.","journal-title":"N Engl J Med"},{"key":"1929_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1086\/379255","volume":"188","author":"FJ Torriani","year":"2003","unstructured":"Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\/HIV coinfection. J Infect Dis. 2003, 188: 1498-1507. 10.1086\/379255.","journal-title":"J Infect Dis"},{"key":"1929_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016\/S0140-6736(01)06102-5.","journal-title":"Lancet"},{"key":"1929_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056\/NEJMoa020047.","journal-title":"N Engl J Med"},{"key":"1929_CR23","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","volume":"18","author":"MS Sulkowski","year":"2004","unstructured":"Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004, 18: 2277-2284. 10.1097\/00002030-200411190-00008.","journal-title":"AIDS"},{"key":"1929_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","volume":"368","author":"J Eron Jr","year":"2006","unstructured":"Eron J, Yeni P, Gathe J, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, et al: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006, 368: 476-482. 10.1016\/S0140-6736(06)69155-1.","journal-title":"Lancet"},{"key":"1929_CR25","doi-asserted-by":"crossref","unstructured":"Miyazaki M, Kato M, Tanaka M, Tanaka K, Takao S, Kohjima M, Ito T, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R: Antithrombin III injection via the portal vein suppresses liver damage. World J Gastroenterol. 18: 1884-1891.","DOI":"10.3748\/wjg.v18.i16.1884"},{"key":"1929_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/cc1854","volume":"7","author":"SM Opal","year":"2003","unstructured":"Opal SM, Esmon CT: Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003, 7: 23-38.","journal-title":"Crit Care"},{"key":"1929_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bbrc.2006.02.190","volume":"343","author":"LF Congote","year":"2006","unstructured":"Congote LF: The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun. 2006, 343: 617-622. 10.1016\/j.bbrc.2006.02.190.","journal-title":"Biochem Biophys Res Commun"},{"key":"1929_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.virusres.2006.12.018","volume":"125","author":"LF Congote","year":"2007","unstructured":"Congote LF: Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers?. Virus Res. 2007, 125: 119-134. 10.1016\/j.virusres.2006.12.018.","journal-title":"Virus Res"},{"issue":"Suppl 1","key":"1929_CR29","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1111\/j.1601-0825.1997.tb00379.x","volume":"3","author":"DC Shugars","year":"1997","unstructured":"Shugars DC, Sauls DL, Weinberg JB: Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis. 1997, 3 (Suppl 1): S70-S72.","journal-title":"Oral Dis"},{"key":"1929_CR30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V90.3.1141","volume":"90","author":"TB McNeely","year":"1997","unstructured":"McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood. 1997, 90: 1141-1149.","journal-title":"Blood"},{"key":"1929_CR31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1172\/JCI118056","volume":"96","author":"TB McNeely","year":"1995","unstructured":"McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995, 96: 456-464. 10.1172\/JCI118056.","journal-title":"J Clin Invest"},{"key":"1929_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1096\/fj.00-0311com","volume":"15","author":"L Shapiro","year":"2001","unstructured":"Shapiro L, Pott GB, Ralston AH: Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 2001, 15: 115-122. 10.1096\/fj.00-0311com.","journal-title":"FASEB J"},{"key":"1929_CR33","first-page":"191","volume":"16","author":"DR Elmaleh","year":"2005","unstructured":"Elmaleh DR, Brown NV, Geiben-Lynn R: Anti-viral activity of human antithrombin III. Int J Mol Med. 2005, 16: 191-200.","journal-title":"Int J Mol Med"},{"key":"1929_CR34","doi-asserted-by":"publisher","first-page":"42352","DOI":"10.1074\/jbc.M207079200","volume":"277","author":"R Geiben-Lynn","year":"2002","unstructured":"Geiben-Lynn R, Brown N, Walker BD, Luster AD: Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem. 2002, 277: 42352-42357. 10.1074\/jbc.M207079200.","journal-title":"J Biol Chem"},{"key":"1929_CR35","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","volume":"96","author":"V Agnello","year":"1999","unstructured":"Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999, 96: 12766-12771. 10.1073\/pnas.96.22.12766.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1929_CR36","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1152\/physrev.00033.2007","volume":"88","author":"AP Lillis","year":"2008","unstructured":"Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008, 88: 887-918. 10.1152\/physrev.00033.2007.","journal-title":"Physiol Rev"},{"key":"1929_CR37","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.bbrc.2005.02.138","volume":"329","author":"M Ikeda","year":"2005","unstructured":"Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N: Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun. 2005, 329: 1350-1359. 10.1016\/j.bbrc.2005.02.138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1929_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199908193410802","volume":"341","author":"MJ Alter","year":"1999","unstructured":"Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999, 341: 556-562. 10.1056\/NEJM199908193410802.","journal-title":"N Engl J Med"},{"key":"1929_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2893.2000.00221.x","volume":"7","author":"LM Blatt","year":"2000","unstructured":"Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, et al: Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000, 7: 196-202. 10.1046\/j.1365-2893.2000.00221.x.","journal-title":"J Viral Hepat"},{"key":"1929_CR40","doi-asserted-by":"publisher","first-page":"e18589","DOI":"10.1371\/journal.pone.0018589","volume":"6","author":"JB Whitney","year":"2011","unstructured":"Whitney JB, Asmal M, Geiben-Lynn R: Serpin Induced Antiviral Activity of Prostaglandin Synthetase-2 against HIV-1 Replication. PLoS One. 2011, 6: e18589-10.1371\/journal.pone.0018589.","journal-title":"PLoS One"},{"key":"1929_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.21232","volume":"44","author":"M Ikeda","year":"2006","unstructured":"Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006, 44: 117-125. 10.1002\/hep.21232.","journal-title":"Hepatology"},{"key":"1929_CR42","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/hep.22849","volume":"49","author":"M Hassan","year":"2009","unstructured":"Hassan M, Selimovic D, Ghozlan H, Abdel-kader O: Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology. 2009, 49: 1469-1482. 10.1002\/hep.22849.","journal-title":"Hepatology"},{"key":"1929_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/1079990041535647","volume":"24","author":"K Miller","year":"2004","unstructured":"Miller K, McArdle S, Gale MJ, Geller DA, Tenoeve B, Hiscott J, Gretch DR, Polyak SJ: Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res. 2004, 24: 391-402. 10.1089\/1079990041535647.","journal-title":"J Interferon Cytokine Res"},{"key":"1929_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.21672","volume":"46","author":"K Matsuzaki","year":"2007","unstructured":"Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, et al: Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007, 46: 48-57. 10.1002\/hep.21672.","journal-title":"Hepatology"},{"key":"1929_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1128\/CMR.00010-06","volume":"20","author":"A Wohnsland","year":"2007","unstructured":"Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007, 20: 23-38. 10.1128\/CMR.00010-06.","journal-title":"Clin Microbiol Rev"},{"key":"1929_CR46","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.3748\/wjg.v13.i17.2446","volume":"13","author":"EF Meurs","year":"2007","unstructured":"Meurs EF, Breiman A: The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol. 2007, 13: 2446-2454.","journal-title":"World J Gastroenterol"},{"key":"1929_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/hep.20371","volume":"40","author":"S Girard","year":"2004","unstructured":"Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Brechot C, Beretta L: Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology. 2004, 40: 708-718. 10.1002\/hep.20371.","journal-title":"Hepatology"},{"key":"1929_CR48","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1111\/j.1440-1746.2006.04380.x","volume":"21","author":"J Dou","year":"2006","unstructured":"Dou J, Liu P, Wang J, Zhang X: Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles. J Gastroenterol Hepatol. 2006, 21: 1794-1800. 10.1111\/j.1440-1746.2006.04380.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1929_CR49","doi-asserted-by":"publisher","first-page":"9237","DOI":"10.1074\/jbc.M808773200","volume":"284","author":"CY Park","year":"2009","unstructured":"Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB: Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem. 2009, 284: 9237-9246. 10.1074\/jbc.M808773200.","journal-title":"J Biol Chem"},{"key":"1929_CR50","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1073\/pnas.87.17.6547","volume":"87","author":"I Saito","year":"1990","unstructured":"Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, et al: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990, 87: 6547-6549. 10.1073\/pnas.87.17.6547.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1929_CR51","doi-asserted-by":"crossref","unstructured":"Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, Lai MM, Akira S, Ou JH: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology. 52: 480-492.","DOI":"10.1002\/hep.23697"},{"key":"1929_CR52","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3748\/wjg.v12.i13.2065","volume":"12","author":"F Farinati","year":"2006","unstructured":"Farinati F, Cardin R, Bortolami M, Guido M, Rugge M: Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol. 2006, 12: 2065-2069.","journal-title":"World J Gastroenterol"},{"key":"1929_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.22070","volume":"47","author":"RT Chung","year":"2008","unstructured":"Chung RT, Gale M, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH: Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008, 47: 306-320.","journal-title":"Hepatology"},{"key":"1929_CR54","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1128\/JVI.76.16.8189-8199.2002","volume":"76","author":"V Castet","year":"2002","unstructured":"Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, Maurel P, Pawlotsky JM: Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol. 2002, 76: 8189-8199. 10.1128\/JVI.76.16.8189-8199.2002.","journal-title":"J Virol"},{"key":"1929_CR55","volume-title":"The Internet Journal of Laboratory Medicine","author":"SMR Sheikh","year":"2009","unstructured":"Sheikh SMR, Viunytska LV: Anithrombin III as a criteria marker in chronic liver disease. The Internet Journal of Laboratory Medicine. 2009, 3:"},{"key":"1929_CR56","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1016\/0002-9343(89)80524-8","volume":"87","author":"SV Pizzo","year":"1989","unstructured":"Pizzo SV: Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med. 1989, 87: 10S-14S.","journal-title":"Am J Med"},{"key":"1929_CR57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1086\/382595","volume":"189","author":"Y Tanabe","year":"2004","unstructured":"Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, et al: Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J Infect Dis. 2004, 189: 1129-1139. 10.1086\/382595.","journal-title":"J Infect Dis"},{"key":"1929_CR58","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.virol.2005.01.008","volume":"333","author":"M Hassan","year":"2005","unstructured":"Hassan M, Ghozlan H, Abdel-Kader O: Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology. 2005, 333: 324-336. 10.1016\/j.virol.2005.01.008.","journal-title":"Virology"},{"key":"1929_CR59","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3748\/wjg.v11.i20.3027","volume":"11","author":"J Cui","year":"2005","unstructured":"Cui J, Dong BW, Liang P, Yu XL, Yu DJ: Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol. 2005, 11: 3027-3033.","journal-title":"World J Gastroenterol"},{"key":"1929_CR60","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1096\/fj.04-3455fje","volume":"19","author":"SW Chan","year":"2005","unstructured":"Chan SW, Egan PA: Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. FASEB J. 2005, 19: 1510-1512.","journal-title":"FASEB J"},{"key":"1929_CR61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.992302","volume":"16","author":"H Nishitoh","year":"2002","unstructured":"Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, Hori S, Kakizuka A, Ichijo H: ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002, 16: 1345-1355. 10.1101\/gad.992302.","journal-title":"Genes Dev"},{"key":"1929_CR62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng1777","volume":"38","author":"JL Babitt","year":"2006","unstructured":"Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, et al: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006, 38: 531-539. 10.1038\/ng1777.","journal-title":"Nat Genet"},{"key":"1929_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.chom.2009.02.001","volume":"5","author":"AW Tai","year":"2009","unstructured":"Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009, 5: 298-307. 10.1016\/j.chom.2009.02.001.","journal-title":"Cell Host Microbe"},{"key":"1929_CR64","first-page":"71","volume":"39","author":"CA Aoki","year":"2005","unstructured":"Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL: Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol. 2005, 39: 71-74.","journal-title":"J Clin Gastroenterol"},{"key":"1929_CR65","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004, 113: 1271-1276.","journal-title":"J Clin Invest"},{"key":"1929_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jhep.2007.08.018","volume":"48","author":"KJ Schmitz","year":"2008","unstructured":"Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008, 48: 83-90. 10.1016\/j.jhep.2007.08.018.","journal-title":"J Hepatol"},{"key":"1929_CR67","doi-asserted-by":"crossref","first-page":"9722","DOI":"10.1128\/JVI.72.12.9722-9728.1998","volume":"72","author":"A Shrivastava","year":"1998","unstructured":"Shrivastava A, Manna SK, Ray R, Aggarwal BB: Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J Virol. 1998, 72: 9722-9728.","journal-title":"J Virol"},{"key":"1929_CR68","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1073\/pnas.96.10.5533","volume":"96","author":"SL Tan","year":"1999","unstructured":"Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG: NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain\/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA. 1999, 96: 5533-5538. 10.1073\/pnas.96.10.5533.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1929_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00705-002-0925-0","volume":"148","author":"U Georgopoulou","year":"2003","unstructured":"Georgopoulou U, Caravokiri K, Mavromara P: Suppression of the ERK1\/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Arch Virol. 2003, 148: 237-251. 10.1007\/s00705-002-0925-0.","journal-title":"Arch Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-9-226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1743-422X-9-226\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-9-226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:45:21Z","timestamp":1594727121000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-9-226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1929"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-9-226","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,2]]},"article-number":"226"}}